Northwestern University: Lymphoma, T-Cell, Cutaneous trials

The registry lists 21 Lymphoma, T-Cell, Cutaneous studies with Northwestern University as lead sponsor. 3 are open to participants now and 6 have results posted.

Early Phase 1 2Phase 1 8Phase 2 10Phase 3 1No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Pilot Study to Characterize the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of CLn® Skin Care Body WashEnrolling by invitationNCT06665490
• Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011® (RLF-TD011®) Spray SolutionNot yet recruitingNCT05728879Early Phase 1
• Characterization of the Microbiome in Cutaneous T Cell LymphomaRecruitingNCT03932279
• Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell LymphomaCompletedNCT02232516Phase 2Results posted
• Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ LymphomasTerminatedNCT01805037Phase 1/2Results posted
• Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell LymphomaTerminatedNCT01738594Phase 1Results posted
• Study of Pegylated Interferon-Alfa 2b in Combination With PUVA Therapy In CTCLTerminatedNCT00724061Not applicableResults posted
• Gemcitabine and Pemetrexed Disodium in Treating Patients With Advanced Mycosis Fungoides or Sézary SyndromeTerminatedNCT00369629Phase 1Results posted
• A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's LymphomaTerminatedNCT00290706Phase 1/2Results posted
• Long-term Use of Romidepsin in Patients With CTCLCompletedNCT02296398
• Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal MetastasesCompletedNCT00424242Early Phase 1
• Alemtuzumab in Treating Patients With Relapsed or Refractory Advanced Mycosis Fungoides or Sézary SyndromeCompletedNCT00057967Phase 2
• Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer or Hematologic CancerCompletedNCT00006225Phase 1/2
• Interleukin-2 in Treating Patients With Mycosis Fungoides or Sezary SyndromeTerminatedNCT00005788Phase 2
• Peripheral Blood Lymphocyte Therapy to Prevent Lymphoproliferative Disorders Caused by Epstein-Barr Virus in Patients Who Have Undergone TransplantationCompletedNCT00005606Phase 2
• Chemotherapy and Radiation Therapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Refractory T-cell Lymphoma, Hodgkin's Lymphoma, or Non-Hodgkin's LymphomaCompletedNCT00004907Phase 1/2
• Stem Cell Transplantation in Treating Patients With Hematologic CancerCompletedNCT00004904Phase 1
• Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic CancerCompletedNCT00004232Phase 1
• Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell TransplantationCompletedNCT00004230Phase 3
• Temozolomide in Treating Patients With Mycosis Fungoides or Sezary SyndromeTerminatedNCT00004106Phase 2
• Tretinoin in Treating Patients With Mycosis Fungoides or Sezary SyndromeCompletedNCT00002479Phase 2